SBRT for liver cancer with limited growth on first immunotherapy
Part of Cancer clinical trials.
This trial tests whether a targeted radiation therapy (SBRT) can help people with liver cancer whose disease has only a few new spots growing while on first-line immunotherapy. It aims to see if zapping those spots can control the cancer and delay the need for stronger treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a confirmed diagnosis of liver cancer (HCC).
- Your cancer has started to grow again in a limited number of spots (5 or fewer) after first-line immunotherapy, such as atezolizumab plus bevacizumab or similar treatments.
- The growing spots can be treated with a precise type of radiation called SBRT, and your liver function is good (Child-Pugh A).
- You have not had radiation to the abdomen or yttrium-90 therapy before, and you do not have an active autoimmune disease or are on high-dose steroids.
- Your blood counts, liver and kidney function must meet certain minimum levels, and you must be able to give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding radiation (SBRT) to a combination of immunotherapy drugs (atezolizumab and bevacizumab) for people with liver cancer that has spread into the main portal vein. It aims to see if this approach can shrink tumors and improve outcomes.
This trial tests whether combining the immunotherapy drug sintilimab with targeted radiation therapy before surgery can improve outcomes for patients with liver cancer that can be surgically removed. It aims to shrink the tumor and reduce the chance of recurrence.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial tests a combination of radiation therapy (SBRT), an immunotherapy drug (camrelizumab), and a targeted therapy drug (apatinib) to shrink liver cancer that cannot be removed with surgery. The goal is to make the cancer small enough for surgery later.
This trial tests a combination of immunotherapy and high-precision radiation (SBRT) to shrink large or multiple liver tumors in people with hepatocellular carcinoma, with the goal of making them small enough for surgery. It's for people who cannot currently have their tumors removed but might become eligible after treatment.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.